TRUMF:OTO-Terumo Corp. (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 16.58

Change

0.00 (0.00)%

Market Cap

USD 12.70B

Volume

1.70K
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 102.50B
ESLOY Essilor International SA

N/A

USD 100.19B
HOCPF HOYA Corporation

N/A

USD 40.96B
HOCPY Hoya Corp

N/A

USD 40.66B
RSMDF Resmed Inc DRC

N/A

USD 28.14B
CLPBF Coloplast A/S

N/A

USD 27.05B
CLPBY Coloplast A

N/A

USD 26.98B
TRUMY Terumo Corp ADR

N/A

USD 24.60B
SAUHF Straumann Holding AG

N/A

USD 21.26B
SAUHY Straumann Holding AG ADR

N/A

USD 19.73B

ETFs Containing TRUMF

DXJH 0.00 % 0.48 %

N/A

N/A
CNKY:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 55.84B
XDJP:LSE Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

USD 321.87B
SXRZ:F iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 56.96B
EXX7:XETRA iShares Nikkei 225 UCITS .. 0.00 % 0.00 %

N/A

USD 28.25B
SXRZ:XETRA iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 58.15B
XDJE:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

USD 0.03B
XDJP:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

USD 157.79B
1329:TSE iShares Core Nikkei 225 E.. 0.00 % 0.00 %

N/A

USD 1,529.93B
1330:TSE Nikko Nikkei 225 Listed 0.00 % 0.00 %

N/A

USD 5,423.56B
1369:TSE DIAM Nikkei 225 0.00 % 0.00 %

N/A

USD 451.27B
1578:TSE Listed Index Fund Nikkei .. 0.00 % 0.00 %

N/A

USD 12.13B
1397:TSE SMDS SMDAM NIKKEI225 ETF 0.00 % 0.00 %

N/A

USD 195.63B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.33% 69% C- 60% D-
Dividend Return 138.43% 96% N/A 99% N/A
Total Return 142.76% 97% N/A 95% A
Trailing 12 Months  
Capital Gain 5.74% 77% C+ 64% D
Dividend Return 140.82% 97% N/A 99% N/A
Total Return 146.56% 97% N/A 94% A
Trailing 5 Years  
Capital Gain 12.03% 70% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.03% 64% D 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 1.61% 35% F 42% F
Dividend Return 29.93% 75% C 69% C-
Total Return 28.32% 100% F 92% A
Risk Return Profile  
Volatility (Standard Deviation) 37.46% 65% D 61% D-
Risk Adjusted Return 79.91% 99% N/A 97% N/A
Market Capitalization 12.70B 90% A- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.